| Drug Name | (Sovaldi®(Sofosbuvir |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Neurology
|
| Risk |
Saudi Food and Drug Authority (SFDA) – Risk of serious symptomatic bradycardia associated with the concomitant use of amiodarone with simeprevir and sofosbuvir |
| safety communication |
|